EpCAM-positive CTCs with a mesenchymal phenotype are more invasive than EpCAM-negative mesenchymal CTCs in mouse models of both metastatic breast cancer and prostate cancer [91,92]. The gene discussed is EPCAM; the disease is prostate cancer.